PDF(Pubmed)
Abstract：
UNASSIGNED: Stereotactic radiosurgery (SRS) has recently gained space as an accepted non-invasive alternative treatment option for drug resistant Glossopharyngeal neuralgia (GPN). The purpose of this systematic review was to provide an overview of the outcomes of SRS treatment in patients with GPN.
UNASSIGNED: A literature review until March 2023 was performed. Data about patient\'s demographics, complications and recurrence rates, additional treatment post procedure as well as pain outcomes in the short and long term were collected. Studies without reported pain outcomes were excluded.
UNASSIGNED: Sixteen studies with a total of 97 patients diagnosed with GPN who had undergone SRS were identified. The mean reported maximal radiation dose ranged from 70 to 88.7 Gy with the glossopharyngeal meatus (GPM) being the most common target in 12/16 studies. The median time from SRS till pain response was between 2 and 120 days. The mean proportion of patients requiring further treatment after SRS ranged from 11.1 to 57.14% in a time frame between 2 and 36 months post procedure. Favourable pain response rates after SRS (BNI-IIIb) ranged from 60% to 100% and 57.1%-100% in short and long term respectively.
UNASSIGNED: SRS for GPN remains a safe alternative to surgery with low complication rates and favourable pain outcomes in both short and long term.
UNASSIGNED: A literature review until March 2023 was performed. Data about patient\'s demographics, complications and recurrence rates, additional treatment post procedure as well as pain outcomes in the short and long term were collected. Studies without reported pain outcomes were excluded.
UNASSIGNED: Sixteen studies with a total of 97 patients diagnosed with GPN who had undergone SRS were identified. The mean reported maximal radiation dose ranged from 70 to 88.7 Gy with the glossopharyngeal meatus (GPM) being the most common target in 12/16 studies. The median time from SRS till pain response was between 2 and 120 days. The mean proportion of patients requiring further treatment after SRS ranged from 11.1 to 57.14% in a time frame between 2 and 36 months post procedure. Favourable pain response rates after SRS (BNI-IIIb) ranged from 60% to 100% and 57.1%-100% in short and long term respectively.
UNASSIGNED: SRS for GPN remains a safe alternative to surgery with low complication rates and favourable pain outcomes in both short and long term.
摘要：
■立体定向放射外科（SRS）最近已成为一种公认的非侵入性治疗耐药舌咽神经痛（GPN）的替代治疗选择。本系统评价的目的是概述GPN患者SRS治疗的结果。
■进行了直到2023年3月的文献综述。有关患者人口统计数据，并发症和复发率，我们收集了术后额外治疗以及短期和长期疼痛结局.没有报告疼痛结果的研究被排除。
■共进行了16项研究，共有97名诊断为GPN的患者接受了SRS。平均报告的最大辐射剂量范围为70至88.7Gy，舌咽道（GPM）是12/16研究中最常见的目标。从SRS到疼痛反应的中位时间在2到120天之间。在手术后2至36个月的时间范围内，SRS后需要进一步治疗的患者的平均比例为11.1％至57.14％。短期和长期SRS（BNI-IIIb）后的良好疼痛反应率分别为60％至100％和57.1％-100％。
■用于GPN的SRS仍然是一种安全的替代手术，在短期和长期并发症发生率低，疼痛效果良好。
■进行了直到2023年3月的文献综述。有关患者人口统计数据，并发症和复发率，我们收集了术后额外治疗以及短期和长期疼痛结局.没有报告疼痛结果的研究被排除。
■共进行了16项研究，共有97名诊断为GPN的患者接受了SRS。平均报告的最大辐射剂量范围为70至88.7Gy，舌咽道（GPM）是12/16研究中最常见的目标。从SRS到疼痛反应的中位时间在2到120天之间。在手术后2至36个月的时间范围内，SRS后需要进一步治疗的患者的平均比例为11.1％至57.14％。短期和长期SRS（BNI-IIIb）后的良好疼痛反应率分别为60％至100％和57.1％-100％。
■用于GPN的SRS仍然是一种安全的替代手术，在短期和长期并发症发生率低，疼痛效果良好。
